Search
Lipocine Inc
LPCNAdd to Watchlist
2.260USD
-0.070-3.00%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
18.63MMarket Cap
LossP/E TTM
More Details of Lipocine Inc Company
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc Info
Ticker SymbolLPCN
Company nameLipocine Inc
IPO dateMar 21, 2014
CEOPatel (Mahesh V)
Number of employees16
Security typeOrdinary Share
Fiscal year-endMar 21
Address675 S Arapeen Dr Ste 202
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84108-1295
Phone18019947383
Websitehttps://www.lipocine.com/
Ticker SymbolLPCN
IPO dateMar 21, 2014
CEOPatel (Mahesh V)
Company Executives of Lipocine Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
203.80K
+79.98%
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
160.68K
+31.12%
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.86K
+9.40%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.40K
+23.64%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, May 11
Updated: Mon, May 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Squadron Capital Management LLC
6.43%
Diadema Partners LP
3.17%
Higuchi (John W)
2.47%
Vanguard Capital Management, LLC
2.43%
Ikarian Capital LLC
2.42%
Other
83.08%
Shareholders
Shareholders
Proportion
Squadron Capital Management LLC
6.43%
Diadema Partners LP
3.17%
Higuchi (John W)
2.47%
Vanguard Capital Management, LLC
2.43%
Ikarian Capital LLC
2.42%
Other
83.08%
Shareholder Types
Shareholders
Proportion
Investment Advisor
10.76%
Hedge Fund
6.90%
Individual Investor
4.51%
Investment Advisor/Hedge Fund
3.05%
Private Equity
1.77%
Research Firm
0.13%
Other
72.89%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
45
2.08M
25.27%
+1.53M
2025Q4
33
1.04M
18.66%
+478.53K
2025Q3
32
528.39K
9.52%
-40.19K
2025Q2
44
680.47K
12.56%
-41.55K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Squadron Capital Management LLC
530.00K
7.26%
+530.00K
--
Dec 31, 2025
Diadema Partners LP
260.94K
3.57%
+260.94K
--
Dec 31, 2025
Higuchi (John W)
40.80K
0.56%
--
--
Mar 31, 2025
Ikarian Capital LLC
199.54K
2.73%
+199.54K
--
Dec 31, 2025
Patel (Mahesh V)
109.05K
1.49%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.22%
--
--
Dec 31, 2025
Geode Capital Management, L.L.C.
62.45K
0.86%
+1.37K
+2.25%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
Date
Ex-dividend Date
Type
Ratio
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
